CP and chronic myelogenous leukemia, BCR-ABL1 positive: However, in the PBMCs of de novo CP-CML patients and BP-CML patients, almost no activation of the DDR proteins was observed, too, despite of the presence of relatively high levels of DNA damage in these cells, as evidenced by γH2AX foci analysis and the presence of ACAs.